Literature DB >> 19199188

The role of gram-negative bacteria in healthcare-associated pneumonia.

Marcos I Restrepo1, Antonio Anzueto.   

Abstract

Healthcare-associated pneumonia (HCAP) is a unique entity that differs from community-acquired pneumonia in both bacteriology and outcomes and has similarities to hospital-acquired pneumonia and ventilator-associated pneumonia. HCAP patients are at higher risk of potential multidrug-resistant pathogens, including resistant gram-negative organisms, especially Pseudomonas aeruginosa and acinetobacter spp., but also extended-spectrum beta-lactamases (ESBLs). This manuscript reviews the epidemiology, etiology, and clinical outcomes of hospitalized HCAP patients due to gram-negative bacteria. We will focus our attention on the potential multidrug-resistant pathogens to suggest a new treatment approach for these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199188     DOI: 10.1055/s-0028-1119810

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  10 in total

1.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

2.  Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.

Authors:  Otgonchimeg Rentsendorj; Mahendra Damarla; Neil R Aggarwal; Ji-Young Choi; Laura Johnston; Franco R D'Alessio; Michael T Crow; David B Pearse
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

Review 3.  Healthcare-associated Pneumonia and Aspiration Pneumonia.

Authors:  Kosaku Komiya; Hiroshi Ishii; Jun-Ichi Kadota
Journal:  Aging Dis       Date:  2014-02-08       Impact factor: 6.745

4.  Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers.

Authors:  David L Tamang; Waheed Pirzai; Gregory P Priebe; David C Traficante; Gerald B Pier; John R Falck; Christophe Morisseau; Bruce D Hammock; Beth A McCormick; Karsten Gronert; Bryan P Hurley
Journal:  J Immunol       Date:  2012-10-08       Impact factor: 5.422

5.  Small molecule screen yields inhibitors of Pseudomonas homoserine lactone-induced host responses.

Authors:  Cathleen D Valentine; Hua Zhang; Puay-Wah Phuan; Juliane Nguyen; A S Verkman; Peter M Haggie
Journal:  Cell Microbiol       Date:  2013-08-22       Impact factor: 3.715

6.  Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia.

Authors:  Wen-Feng Fang; Kuang-Yao Yang; Chieh-Liang Wu; Chong-Jen Yu; Chang-Wen Chen; Chih-Yen Tu; Meng-Chih Lin
Journal:  Crit Care       Date:  2011-01-19       Impact factor: 9.097

7.  Contaminated open fracture and crush injury: a murine model.

Authors:  Shawn R Gilbert; Justin Camara; Richard Camara; Lynn Duffy; Ken Waites; Hyunki Kim; Kurt Zinn
Journal:  Bone Res       Date:  2015-01-27       Impact factor: 13.567

Review 8.  The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.

Authors:  Teiji Sawa
Journal:  J Intensive Care       Date:  2014-02-18

9.  Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype.

Authors:  Melissa Agnello; Steven E Finkel; Annie Wong-Beringer
Journal:  Front Microbiol       Date:  2016-10-04       Impact factor: 5.640

10.  Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  BMC Pharmacol Toxicol       Date:  2016-03-23       Impact factor: 2.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.